Research programme: thrombin inhibitors - Matrix Pharma
Latest Information Update: 16 Jul 2016
At a glance
- Originator Matrix Pharma
- Class
- Mechanism of Action Thrombin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Stroke; Thromboembolism
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Stroke in United Kingdom (PO)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Thromboembolism in United Kingdom (PO)
- 18 Jan 2006 Preclinical trials in Stroke in United Kingdom (PO)